Company Filing History:
Years Active: 2015-2016
Title: Young-Woo Park: Innovator in Monoclonal Antibody Research
Introduction
Young-Woo Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, his work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Young-Woo Park's latest patents is titled "Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof." This invention relates to human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. More specifically, it involves human ScFv molecules that inhibit angiogenesis and provide compositions for cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptors. It has shown effectiveness in neutralizing these receptors in humans, mice, and rats, making it a valuable asset in anticancer studies.
Career Highlights
Young-Woo Park is currently associated with Pharmabcine Inc., where he continues to advance his research in monoclonal antibodies. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies.
Collaborations
Throughout his career, Young-Woo Park has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee. These partnerships have contributed to the success of his research and the development of innovative solutions in the field.
Conclusion
Young-Woo Park is a distinguished inventor whose work in monoclonal antibody research holds promise for future cancer treatments. His innovative contributions continue to shape the landscape of biomedical research and offer hope for improved therapeutic options.